Powerful clot-blocking drug fails to beat standard pills in stubborn stroke subtype

A large randomized clinical trial has delivered a sobering verdict on one of the most widely used empirical treatments in stroke medicine. Intravenous tirofiban, a potent antiplatelet drug that many physicians have reached for when treating a notoriously unpredictable form of ischemic stroke, did not outperform standard oral antiplatelet therapy in improving patients’ functional recovery at 90 days. The findings, published in The Lancet Regional Health – Western Pacific, come from the BRANT trial, a phase III study conducted at 25 hospitals in China and the first adequately powered randomized trial to focus specifically on branch atheromatous disease-related stroke.

Branch atheromatous disease, often abbreviated as BAD, is a distinct and clinically consequential subtype of acute ischemic stroke, accounting for roughly 9 to 20 percent of cases. First described by neurologist Louis Caplan in 1989, it involves atherosclerotic disease at the origin of penetrating arteries, the small deep vessels that branch off major cerebral arteries such as the middle cerebral artery and the basilar artery. This mechanism differs fundamentally from lacunar infarction caused by lipohyalinosis, and BAD is not well captured by the conventional TOAST classification system that has long organized ischemic stroke subtypes. With advances in magnetic resonance imaging, BAD is increasingly recognized as a single subcortical infarction extending along a perforator territory without severe stenosis of the parent artery.

What makes BAD so clinically troubling is its tendency toward early neurological deterioration, a phenomenon in which patients who initially present with mild deficits suddenly worsen, sometimes dramatically, within hours or days of onset. More than 30 percent of patients with BAD remain disabled at follow-up, a striking figure given that many arrive at the hospital with only minor symptoms. Paradoxically, the annual risk of recurrent stroke in BAD is relatively low, at less than 3.8 percent. This high disability, low recurrence profile suggests that the most meaningful treatment goal in this population is preventing early deterioration and improving functional outcome, rather than preventing recurrent ischemic events. Yet the mechanisms driving deterioration, including perforator hypoperfusion, local thrombosis, and inflammation, remain incompletely understood, and no guideline-endorsed therapy specifically addresses this subtype. Intravenous alteplase has not consistently prevented deterioration, and most patients lack a target suitable for mechanical thrombectomy.

Into this therapeutic vacuum stepped tirofiban, a reversible antagonist of the glycoprotein IIb/IIIa receptor on platelets. By blocking this receptor, tirofiban rapidly and potently inhibits platelet aggregation, the cellular process at the heart of clot formation. Prior randomized trials had suggested that tirofiban could safely improve outcomes in select acute ischemic stroke populations, including patients with disabling non-cardioembolic stroke and those receiving it as an adjunct after intravenous thrombolysis or endovascular treatment. On the strength of this indirect evidence, clinicians increasingly administered tirofiban empirically to patients with BAD-related stroke, despite the absence of randomized data in that specific population. The BRANT trial was designed to test whether this common practice was actually justified.

The trial enrolled adults aged 18 to 75 years who presented within 48 hours of stroke onset and met strict MRI-based diagnostic criteria for BAD, defined as a single deep subcortical infarction in the territory of a lenticulostriate or paramedian pontine artery without more than 50 percent stenosis of the corresponding parent artery. Eligibility was confirmed through centralized imaging review, and patients with transient ischemic attack, cardioembolic sources, significant large-artery stenosis, or plans to receive thrombolysis or endovascular therapy were excluded. Between November 2023 and November 2025, 516 patients were randomly assigned in a 1:1 ratio to receive either intravenous tirofiban or guideline-based antiplatelet therapy. The tirofiban regimen consisted of a loading infusion of 0.4 micrograms per kilogram per minute for 30 minutes, followed by a maintenance infusion of 0.1 micrograms per kilogram per minute for 48 hours. The control group received either aspirin alone or aspirin plus clopidogrel for 48 hours, at the treating physician’s discretion. Although the trial was open-label, the statisticians, members of the independent clinical events committee, and outcome assessors were blinded to treatment allocation, protecting the integrity of the endpoint measurements.

The primary endpoint was an excellent functional outcome at 90 days, defined as a score of 0 or 1 on the modified Rankin Scale, which ranges from 0 for no symptoms to 6 for death. The results were unequivocally negative for superiority. At 90 days, 181 of 258 patients in the tirofiban group, or 70.2 percent, achieved an excellent functional outcome, compared with 178 of 255 patients, or 69.8 percent, in the standard antiplatelet group. The unadjusted risk ratio was 1.01 with a 95 percent confidence interval of 0.90 to 1.13, and the P value of 0.93 left no statistical ambiguity: the two strategies produced essentially identical outcomes. Adjusted analyses and per-protocol analyses yielded the same conclusion, and prespecified subgroup analyses across six baseline characteristics, including age, sex, hypertension, diabetes, stroke severity, and time from onset to randomization, found no hint of treatment effect heterogeneity.

Secondary outcomes told a similarly flat story. The rate of early neurological deterioration within seven days after randomization was 8.2 percent in the tirofiban group versus 6.3 percent in the control group, a difference that was not statistically significant and, if anything, numerically favored standard therapy. Ordinal modified Rankin Scale scores at 90 days, National Institutes of Health Stroke Scale scores at 7 and 90 days, and Barthel Index scores of daily independence at 90 days all showed no meaningful advantage for tirofiban. Recurrent ischemic events were rare in both arms, with ischemic stroke occurring in 1.9 percent of tirofiban patients and 1.6 percent of control patients within 90 days, consistent with the characteristically low recurrence risk of this stroke subtype.

On the safety side, major bleeding, defined by the PLATO criteria, was strikingly rare: zero events among 259 tirofiban-exposed patients with available safety assessments versus one event among 245 control patients, and no intracranial hemorrhage occurred in the tirofiban group. Rates of serious adverse events and all-cause death were similar between groups. However, the investigators caution that such a small number of bleeding events precludes any precise comparative safety conclusion, and the findings should not be interpreted as establishing equivalent safety between the two strategies.

The negative result takes on added significance when placed alongside the broader landscape of tirofiban research. The RESCUE BT2 trial, which enrolled patients with ischemic stroke without medium or large vessel occlusion, found that early tirofiban improved the proportion achieving excellent functional outcomes, but that cohort had a higher median baseline stroke severity and a mixture of etiologies, leaving the benefit for BAD specifically unclear. The TREND trial found tirofiban reduced early neurological deterioration in non-cardioembolic strokes, but 58 percent of its participants had large artery atherosclerosis or unknown etiology. Meanwhile, the STRATEGY trial, which also targeted BAD-related stroke, similarly found that tirofiban failed to reduce deterioration. One notable feature of BRANT is that 85.5 percent of control patients received dual antiplatelet therapy during the randomized period, a level of background platelet inhibition that may itself have attenuated any incremental benefit of adding tirofiban, since the control group may already have achieved substantial antithrombotic effect.

The trial’s authors are careful to frame what the result does and does not mean. Most patients were randomized relatively late after stroke onset, with a median time from onset to randomization of about 30 hours, and more than half of all early neurological deterioration events had already occurred before randomization, limiting any opportunity for tirofiban to intervene. Concomitant oral antiplatelet therapy was also prohibited during the tirofiban infusion, a design feature that distinguishes this regimen from other tirofiban-based strategies. The findings therefore do not constitute evidence against all tirofiban-based treatment approaches, nor do they establish equivalence between the two strategies. What they do establish, with the rigor of a well-powered randomized design, is that routine empirical use of intravenous tirofiban monotherapy cannot be recommended over standard oral antiplatelets for BAD-related stroke presenting within 48 hours of onset. Future trials, the investigators suggest, should explore whether ultra-early intervention, treatment of patients with active deterioration, or alternative pathophysiological targets might finally deliver the clinical benefit that has so far eluded this stubborn and disabling stroke subtype.

Subject of Research: A phase III randomized trial of intravenous tirofiban versus standard antiplatelet therapy for acute branch atheromatous disease-related ischemic stroke

Article Title: Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial

Article References: Li, S., Hu, H., Zhang, D., Liu, B., Zhong, M., Wang, L., Yang, Q., Zhang, P., Zhao, W., Zhao, F., Tang, Y., Wang, X., Li, H., Chen, L., Chen, G., Wang, R., Dong, A., Zheng, Z., Wang, X., … Zhang, L. (2026). Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial. The Lancet Regional Health – Western Pacific, 75, Article 101995. https://doi.org/10.1016/j.lanwpc.2026.101995

Image Credits: AI Generated

DOI: 10.1016/j.lanwpc.2026.101995

Keywords: tirofiban, branch atheromatous disease, ischemic stroke, antiplatelet therapy, early neurological deterioration, randomized controlled trial, glycoprotein IIb/IIIa inhibitor, perforating arteries, modified Rankin Scale, stroke outcomes, dual antiplatelet therapy, BRANT trial